Ritlecitinib for the treatment of severe alopecia areata: real-world experience from a UK tertiary centre

Key Points

• To assess the safety and efficacy of Ritlecitinib for patients with severe alopecia areata.
• Evaluated patient data from routine clinical care.
• Conducted audits of new therapies to monitor outcomes.
• No additional ethics were required for assessments.
• Demonstrated safety of Ritlecitinib in real-world settings.
• Efficacy results showed positive outcomes for severe alopecia areata patients.

Abstract